Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 551 - 600 out of 41,456

Document Document Title
WO/2022/170379A1
The present invention relates to a method of preparing a topical pharmaceutical composition, a pharmaceutical composition prepared by the method, a topical pharmaceutical composition, and to uses and methods involving the pharmaceutical ...  
WO/2022/103966A9
Provided herein are methods of treating heart failure in patients exhibiting one or more additional features, comprising administering to the patient a therapeutically effective amount of omecamtiv mecarbil, or a hydrate, salt, or salt o...  
WO/2022/171151A1
The present disclosure relates to an SMTP-7 derivative and the use thereof. In particular, provided is a compound as represented by formula I or a pharmaceutically acceptable salt thereof, wherein each group is as defined in the descript...  
WO/2022/173818A1
Provided are methods for reducing the risk of drug-related hemolysis toxicity in subjects receiving primaquine and/or tafenoquine, for improving the therapeutic index of primaquine and/or tafenoquine in subjects, and for reducing the pro...  
WO/2022/133061A9
Provided herein are cryopreservation compositions, e.g., infusion-ready cryopreservation compositions, pharmaceutical compositions comprising cryopreservation compositions, e.g., infusion-ready cryopreservation compositions, and methods ...  
WO/2022/172006A1
The present invention relates to treatments of hereditary angioedema (HAE). In particular, the present invention provides on‐demand treatments of hereditary angioedema (HAE) by orally administering a plasma kallikrein inhibitor to a pa...  
WO/2022/167778A1
Ebselen, 2-Phenyl-1,2-benzisoselenazol-3(2H)-one, (I) is a modulator of the adenosine A2A receptor and is indicated for use in the treatment or prevention of a disease or condition mediated by the adenosine A2A receptor.  
WO/2022/169957A1
Photosynthetic compositions, methods of preparing photosynthetic compositions, and methods of using photosynthetic compositions are provided herein. Some photosynthetic compositions can be perfusable and comprise photosynthetic cells sus...  
WO/2022/170200A1
The present invention refers to l-(2-sulfonyl-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl]-ethanone derivatives of formula (I) as pyruvate kinase (PKR) and/or PKM2 activators for use in the treatment of sickle cell disease, sickle cell an...  
WO/2022/169946A1
The present disclosure provides methods and compositions for treating a condition associated with impaired lymphatic drainage.  
WO/2022/169206A1
The present invention relates to a method for purification of hemopexin and haptoglobin and provides a method in which a solution containing hemopexin and haptoglobin is titrated to a range of specific pH values without a step of precipi...  
WO/2022/166845A1
The present invention relates to a compound of formula (I) capable of inhibiting plasmin activity and having blood coagulation and hemostasis activity, and a pharmaceutically acceptable salt, hydrate, isomer, prodrug, and mixture thereof...  
WO/2022/166581A1
A nucleotide derivative, a pharmaceutical composition thereof, and a use thereof. Specifically disclosed are a nucleotide derivative represented by formula (I) or a tautomer, a stereoisomer, a solvate, a pharmaceutically acceptable salt ...  
WO/2022/162625A1
Antibody formulations and methods useful for treatment of patients with AL amyloidosis.  
WO/2022/162232A1
The present invention relates to a methanobactin reducing Fe3+ ions to Fe2+ ions for use in medicine and a pharmaceutical composition comprising said methanobactin as well as to a process for reducing Fe3+ ions to Fe2+ ions ex vivo.  
WO/2022/164392A1
The present invention relates to methods modifying cell surface markers of red blood cells (RBCs) and uses of the same. In particular, the method comprises contacting an RBC with a peptide in the presence of a ligase, under suitable cond...  
WO/2022/165242A1
In various embodiments method are provided for generating expression cassettes and gene therapy vectors comprising those cassettes that recapitulate the spatiotemporal pattern of expression of the endogenous gene. In certain embodiments ...  
WO/2022/165130A1
Antibodies and compositions containing such antibodies or antigen binding fragments thereof that bind plasma kallikrein are provided herein. Also provided are methods of making and using such antibodies or antigen binding fragments there...  
WO/2022/165390A1
Methods and compositions are provided that allow for high-level expression of a factor VIII polypeptide. More specifically, methods and compositions are provided comprising nucleic acid and amino acid sequences comprising a modified fact...  
WO/2022/157676A1
The present invention relates to methods of preserving the integrity of peptides in the gut. In particular, it concerns the use of certain compounds as inhibitors of gut proteases.  
WO/2022/157686A1
The present invention relates to a new compound that can inhibit an anoctamin 6 protein, a composition comprising the compound, a method for preparing the compound, and a method for using the compound or composition.  
WO/2022/156799A1
The present invention relates to an antibody, which mainly binds to plasma prekallikrein, and the use of the antibody in the preparation of a drug for preventing or treating diseases associated with plasma kallikrein or plasma prekallikr...  
WO/2022/156240A1
A method for preparing a Xuesaitong dispersible tablet, the method comprising: micronizing Panax notoginseng saponins as a raw material, adding water and calcium hydrophosphate, adding an acid, and stirring same until there is no precipi...  
WO/2022/156798A1
Provided are an antibody that binds to a plasma kallikrein and the use of the antibody in the preparation of a medicament for the prevention or treatment of a disease associated with the plasma kallikrein or with a plasma prekallikrein.  
WO/2022/155716A1
The present invention pertains to the fields of pharmaceutics, medicine, biotechnology and immunology. More specifically, the present invention describes the use of a compound or of a combination of compounds for preparing a pharmaceutic...  
WO/2022/159373A1
Provided are methods for clinical treatment of complement-mediated TMA (CM- TMA) (e.g., CM-TMA associated with a trigger, such as autoimmune condition, an infection, a transplant, one or more drugs, or malignant hypertension), using an a...  
WO/2022/155706A1
The present invention relates to chimeric and fusion proteins and their compositions, and the use of such proteins and compositions in the prevention and/or treatment diseases or conditions requiring plasminogen supplementation. In one a...  
WO/2022/157722A1
The present invention relates to a heparan sulfate compound of formula (I) & (II) or a pharmaceutically acceptable salt thereof and pharmaceutical composition containing them. The present invention also relates to a process for preparing...  
WO/2022/156193A1
A comprehensive antimicrobial therapy for urticaria and allergic/allergic reaction constitutions. The technical field relates to medical dermatology/allergic reaction department, traditional Chinese medicine/science of Chinese pharmacolo...  
WO/2022/087405A9
The present disclosure provides compositions, kits, and methods relating to the identification and treatment of immunothrombotic conditions. In particular, the present disclosure provides novel compositions and methods for identifying wh...  
WO/2022/151669A1
Provided is an isolated strain of Lactobacillus amylovorus LAM1345, which is deposited at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH under an accession number DSM 33510. Also provided are a composition including the isol...  
WO/2022/155352A1
The present disclosure relates to a formulations and methods for transdermal delivery of a medicament through the skin of a subject. In aspects, the formulation comprises a therapeutically effective amount of a medicament and a penetrant...  
WO/2022/155435A1
This document relates to methods and materials for treating a mammal (e.g., a human) having, or at risk of developing, a polycystic disease (e.g., a polycystic kidney disease (PKD)). For example, methods and materials that can be used to...  
WO/2022/152141A2
Provided herein are polymer conjugated lipid compounds that can be used in combination with other lipid components, such as cationic lipids, neutral lipids, and cholesterol, to form lipid nanoparticles for delivery of therapeutic agents ...  
WO/2022/155614A1
Disclosed herein are compounds of Formula (I-A), wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used as antioxidant ...  
WO/2022/155674A1
The present disclosure relates to compounds, and to their pharmaceutical compositions, that inhibit dipeptidyl peptidase IV (DPP4). Hie compounds selectively promote the proliferation of alveolar type 2 cells (AEC2s) and are useful in th...  
WO/2022/152282A1
CD22 antibodies, a preparation method therefor, and an application thereof. The CD22 antibodies have a high affinity to CD22 protein. Therefore, the CD22 antibodies can be used in the preparation of drugs for the treatment of diseases su...  
WO/2022/150927A1
The present disclosure is generally directed to a delivery device for the automatic injection of at least two doses of a fluid into the IM site of a subject during at least two different stages of operation. The delivery device generally...  
WO/2022/150621A1
This invention provides methods for the treatment of anemia in patients with chronic kidney disease (CKD) using vadadustat (Compound 1). Methods described herein provide alternative dosing regimens for patients having anemia. In addition...  
WO/2022/150624A1
The present invention provides novel antigen binding peptides, such as an antibody or antibody fragment, that specifically bind to selective FXIa inhibitors and/or dual inhibitors of FXIa, and plasma kallikrein. The present invention fur...  
WO/2022/150623A1
Provided herein are therapeutic methods comprising administering a compound (e.g., a first compound) that is a hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor in combination with a compound (e.g., a second compound) that i...  
WO/2022/147962A1
The present invention relates to the field of hemodialysis, in particular to a fat emulsion dialysate, and a preparation method therefor and the use thereof. Provided in the present invention is a fat emulsion dialysate, comprising long-...  
WO/2022/147759A1
A gRNA molecule targeting Intron I or Intron II of β-globin gene, a synthetic method thereof, a method for constructing a repair system targeting β-globin gene mutation sites, a repair system, and a universal method to correct types of...  
WO/2022/149010A1
The present invention relates to compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, and polymorphs. The invention also relates to processes for ...  
WO/2022/143675A1
A culture medium composition for amplifying and maintaining self-renewal capacity and differentiation potential of hematopoietic stem cells (HSCs), a cell population and an application thereof. The culture medium composition comprises a ...  
WO/2022/143911A1
A compound of formula (I) capable of inhibiting plasmin activity and delaying fibrinolysis, and having coagulation and hemostasis activity, a pharmaceutically acceptable salt thereof, a hydrate thereof, an isomer thereof, a prodrug there...  
WO/2022/143513A1
The present invention relates to an oral preparation comprising Erigeron breviscapus, and a preparation method therefor and an application thereof, the preparation comprising common oral dosage forms such as capsules, tablets, oral liqui...  
WO/2022/145144A1
The present invention provides: a pharmaceutical composition for treating X-linked sideroblastic anemia, the composition comprising a demethylating agent, in particular, 5−azacitidine or a derivative thereof; and normal erythroid cells...  
WO/2022/141684A1
Provided are a crystal form A, crystal form B, crystal form C and amorphous form of honokiol and a preparation method therefor. The method comprises: dissolving honokiol in n-heptane, standing at room temperature overnight, the precipita...  
WO/2022/135421A1
Disclosed in the present invention are a salt form of an isoquinolinone type compound as a ROCK protein kinase inhibitor and a preparation method therefor; and use of the salt form in the preparation of a medicament for treating diseases...  

Matches 551 - 600 out of 41,456